Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7048
Gene Symbol: TGFBR2
TGFBR2
0.400 Biomarker phenotype CTD_human Clinical features in a family with an R460H mutation in transforming growth factor beta receptor 2 gene. 16885183 2006
Entrez Id: 7048
Gene Symbol: TGFBR2
TGFBR2
0.400 Biomarker phenotype HPO
Entrez Id: 2056
Gene Symbol: EPO
EPO
0.330 Biomarker phenotype BEFREE Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in recipients of hsct. 29719440 2018
Entrez Id: 2056
Gene Symbol: EPO
EPO
0.330 Biomarker phenotype BEFREE Combined treatment with EPO and EA was well tolerated, and all 18 patients who suffered from fatigue prior to therapy recovered. 27271482 2017
Entrez Id: 2056
Gene Symbol: EPO
EPO
0.330 Therapeutic phenotype CTD_human A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. 18695134 2008
Entrez Id: 2056
Gene Symbol: EPO
EPO
0.330 Biomarker phenotype BEFREE Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. 15856028 2005
Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
0.310 Biomarker phenotype CTD_human Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. 8759893 1996
Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
0.310 Biomarker phenotype BEFREE Side effects of IFNa (fatigue, anorexia, weight loss) were frequent, and 3 patients decided to drop out of the treatment. 7770930 1995
Entrez Id: 8797
Gene Symbol: TNFRSF10A
TNFRSF10A
0.300 Biomarker phenotype CTD_human Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. 19652058 2009
Entrez Id: 210
Gene Symbol: ALAD
ALAD
0.200 Biomarker phenotype RGD We also examined the activity of the enzyme ALA dehydratase (ALAD), which is the second enzyme in the heme biosynthetic pathway, and ALAD gene expression during the fatigue and its recovery sessions. 17204241 2007
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 Biomarker phenotype BEFREE Naturally occurring human mutations influence a wide range of CBG properties and point toward a role in hitherto unexplained chronic musculoskeletal pain and fatigue disorders as well as potentially affecting fertility outcomes including offspring gender. 27214312 2016
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 GeneticVariation phenotype BEFREE Corticosteroid-binding globulin (CBG; SERPIN A6) gene mutations are rare; only four mutations have been described, often in association with fatigue and chronic pain, albeit with incomplete penetrance. 22013108 2012
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 GeneticVariation phenotype BEFREE Rare kindreds with CBG mutations reducing CBG levels or altering binding affinity have been described, along with clinical manifestations encompassing fatigue, chronic pain, and hypotension. 21795453 2011
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 GeneticVariation phenotype BEFREE The mechanisms by which CBG mutations may cause fatigue are unknown. 19643166 2010
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 GeneticVariation phenotype LHGDN To the best of our knowledge, this case represents the first de novo mutation reported for corticosteroid-binding globulin deficiency, implicating a pathogenic role of variants of SERPINA6 in some cases of muscle fatigue. 17245537 2007
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 GeneticVariation phenotype BEFREE To the best of our knowledge, this case represents the first de novo mutation reported for corticosteroid-binding globulin deficiency, implicating a pathogenic role of variants of SERPINA6 in some cases of muscle fatigue. 17245537 2007
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 AlteredExpression phenotype BEFREE A mechanism for the effect of CBG mutations on fatigue is not readily apparent because free cortisol levels are normal, although we speculate that CBG may have an effect on cortisol-brain transport. 17547679 2007
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 GeneticVariation phenotype LHGDN Association between chronic fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224 polymorphism. 15554358 2004
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 GeneticVariation phenotype BEFREE Although relative hypotension and fatigue have recently been associated with CBG deficiency in a family with two CBG mutations (null and Lyon), the two homozygous subjects in this kindred were both normotensive and only the proband presented with fatigue. 12780753 2003
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 Biomarker phenotype BEFREE As idiopathic fatigue disorders are associated with relatively low plasma cortisol, abnormalities of corticosteroid-binding globulin may be pathogenic. 11502797 2001
Entrez Id: 866
Gene Symbol: SERPINA6
SERPINA6
0.190 Biomarker phenotype HPO
Entrez Id: 213
Gene Symbol: ALB
ALB
0.160 Biomarker phenotype BEFREE The aim of this study was to investigate the predictive factors of objective response rate (ORR) and progression-free survival (PFS), and the correlation of albumin-bilirubin (ALBI) grade with decreased appetite and fatigue in hepatocellular carcinoma patients treated with lenvatinib. 31760660 2020
Entrez Id: 213
Gene Symbol: ALB
ALB
0.160 AlteredExpression phenotype BEFREE After adjustments of variables, female sex, younger age at diagnosis, and lower serum albumin level were independently associated with fatigue scores, while a longer follow-up period and lower serum albumin levels were associated with itch scores. 30135523 2018
Entrez Id: 213
Gene Symbol: ALB
ALB
0.160 AlteredExpression phenotype BEFREE The improvement in pain and fatigue was supported by the ECOG performance status remaining stable with the highest score being equal to 2 throughout the study and a trend towards an improvement in GPS performance status and albumin levels. 30519091 2018
Entrez Id: 213
Gene Symbol: ALB
ALB
0.160 GeneticVariation phenotype BEFREE We assessed fatigue using three fatigue scales-the Brief Fatigue Inventory (BFI), the Edmonton Symptom Assessment System (ESAS), and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30)-and determined their association with objective assessments, including handgrip strength, maximal inspiratory pressure, lean body mass, phase angle, and albumin. 28063860 2017